Polycythemia Vera: outcomes, unmet needs, and therapeutic strategies
vjhemonc.com/video/4kie_7r9...
Jerry L. Spivak
Jerry L. Spivak, MD, Johns Hopkins Medicine, Baltimore, MD, outlines the disease outcomes, unmet needs and therapeutic strategies in patients with polycythemia vera (PV). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Interesting presentation by Dr. Spivak. It really speaks to the importance of :First do no harm" that so many docs seem to forget. Dr. Spivak was my former MPN consultant prior to his semi-retirement. He took me off aspirin at age 63 saying "You really do not want to get a brain bleed. " Two weeks later, I was diagnosed with a hemorrhagic brain tumor surrounded by edema. Stopping aspirin was a really good thing. I really like his mantra that PV is not a monolithic disease. Each person has to be evaluated individually. It is what we all need and deserve.
MPN Symptom UncoveredLong-Term Use of Besremi in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension
Combined ruxolitinib and pegasys therapy for MF and PV gives great results. Danish phase 2 study Jan 2020 ( ruxopeg) 
Hydroxyurea with eliquis or aspirin
Dx of ET vs PV
